Presentation is loading. Please wait.

Presentation is loading. Please wait.

UPDATE IN THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODIES SILVIA S. PIERANGELI, PhD LOUISVILLE APL DIAGNOSTICS, INC DORAVILLE, GA USA Louisville APL Diagnostics,

Published by Modified over 9 years ago

Similar presentations

Presentation on theme: "UPDATE IN THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODIES SILVIA S. PIERANGELI, PhD LOUISVILLE APL DIAGNOSTICS, INC DORAVILLE, GA USA Louisville APL Diagnostics,"— Presentation transcript:

1 UPDATE IN THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODIES SILVIA S. PIERANGELI, PhD LOUISVILLE APL DIAGNOSTICS, INC DORAVILLE, GA USA Louisville APL Diagnostics, Inc

2 Louisville APL Diagnostics 1984-1985 n Problems with false positive results n aCL positive in a wide variety of infectious diseases and in non-APS related autoimmune diseases.

3 Louisville APL Diagnostics

4 ANTIPHOSPHOLIPID SYNDROME Diagnostic Testing n 1.) Laboratory confirmation is vital for diagnosis of APS. n 2.) Anticardiolipin antibody and lupus anticoagulant tests together diagnose vast majority of APS patients-these tests are relatively standard and well understood. n 3.) More specific test for APS should be developed and broadly tested (include anti-cardiolipin positive/APS negative sera in testing). n 4.) More specific tests may enable confirmation of diagnosis in equivocal and unusual clinical presentations to APS.

5 Louisville APL Diagnostics ANTIPHOSPHOLIPID SYNDROME Laboratory Tests n Tests should be positive in most patients with disorder (sensitivity). n Tests should be largely confined to patients with disorder (specificity) n Tests should be performed reproducibly in most laboratories.

6 Louisville APL Diagnostics APhL ® ELISA Kit - Principle n Based on observation that antiphospholipid antibodies crossreact with negatively charged phospholipids but syphilis and other infectious diseases sera largely limited to cardiolipin binding (no crossreactivity) n Construction of a kit with negatively charged phospholipids might eliminate non-specific binding.

7 Louisville APL Diagnostics ANTI-CARDIOLIPIN ANTIBODIES n BINDS n Cardiolipin n Phosphatidylserine n Phosphatidylglycerol n Phosphatidic Acid n DOES NOT BIND n Phosphatidylcholine n ?phosphatidylethanolamine

8

9

10 Louisville APL Diagnostics Sensitivity of the assays Relative Sensitivity/Specificity

11 Louisville APL Diagnostics Prevalence of aCL, APL and anti-  2 GPI in various infectious diseases

12 Louisville APL Diagnostics Evaluation of different assays to diagnose APS: Multicenter study. n Samples tested: n APS=56 n Healthy controls=145 n Non-APS including infectious diseases (syphilis, HIV, other autoimmune diseases)= 206.

13 Louisville APL Diagnostics Evaluation of different assays to diagnose APS. n *Centers involved and assays utilized: n Univ Texas San Antonio: APhL ® ELISA test. Morehouse School of Medicine: aCL (in-house) and anti-  2 GPI (INOVA) Morehouse School of Medicine: aCL (in-house) and anti-  2 GPI (INOVA) University of Milan: in-house anti-  2 GPI and anti-prothrombin. University of Milan: in-house anti-  2 GPI and anti-prothrombin. n * participating centers were blind to the identity of the samples n Univ of Utah: Coordinating center.

14 Louisville APL Diagnostics Sensitivity and Specificity of the assays Assay APS samples # positives (sensitivity) Healthy controls # positives Other diseases # positives Non-APS combined # positives Specificity Positive Predictive value aCL(in-house) 42/56 (75%) 1/150 (0.6%) 27/206 (13%) 28/356 (7.8%) 91.8%59.1% a   GPI (INOVA) 44/56 (78.5%) 15/143 (10.5%) 58/197 (29.4%) 73/340 (21.4%) 78.6%37.6% aPT (in- house) 13/54 (24%) 15/132 (11.3%) 19/178 (10.7%) 34/310 (10.9%) 88.4%25.4% a   GP(in- house) 43/54(79.6%)13/145(8.9%) 9/192 (4.6%) 22/337 (6.5%) 93.2%65.1% APhL ELISA kit 45/56 (80.3%) 4/147 (2.7%) 14/204 (6.8%) 18/351 (5.1%) 94.0%68.1%

15 Louisville APL Diagnostics Evaluation of CAP survey samples in FDA aCL approved assays Sample Kit 1 Kit 2 Kit 3 APhLResult 99-4negnegnegnegneg 99-694.295.6>200>200pos 00-1negnegnegnegneg 00-2negnegnegnegneg 00-393.39166.769.8pos 01-450.156.150.050.9pos 01-5negnegnegnegneg 01-624.415.426.526.4pos 02-1negnegnegnegneg 02-2negnegnegnegneg 02-3negnegnegnegNeg

16 Louisville APL Diagnostics CAP survey results: IgG APhL ELISA

17 Louisville APL Diagnostics CAP survey: IgM APhL

18 Louisville APL Diagnostics APhL ® ELISA kit n Six pre-diluted calibrators (ready to use) n 3 x 30 minutes incubation steps n Peroxidase and alkaline phosphatase systems available n All other reagents in “ready-to-use” form n Determination of IgG and IgM aPL antibodies n 12 month expiration date. n Good to be used in automated systems.

19 Louisville APL Diagnostics APhL ® ELISA kit n Antigen composed fo mixture of phospholipids - ß 2 GP1 n Sensitivity of APS (greater than 90%) n More specific than anticardiolipin test and at least as specific (or more) compared to anti-ß 2 GP1 n Incorporation of an in-house positive control n Can be utilized for first line testing, and certainly important in confirmation of APS

20 Louisville APL Diagnostics Conclusion n Since sensitivity of APhL ® ELISA kit is comparable to anticardiolipin test, it can be used for first line testing in place of the anticardiolipin test. The APhL ® ELISA kit will enable greater specificity - APS diagnosis

21 Clinical Features of APS Anticardiolipin (IgG, IgM) and Lupus anticoagulant tests (APhL ELISA ® test) Negative Anticardiolipin and Negative Lupus anticoagulant but Highly Suggestive Clinical Features Low Positive Anticardiolipin High/Medium Positive Anticardiolipin or Positive Lupus anticoagulant anti-  2 GP1 or APhL ELISA ® Test NegativePositive aCL Antiphospholipid Syndrome Confirmation with anti-  2 GP1 or APhL ELISA ® test Both NegativeEither Positive Consider IgA Anticardiolipin Antiphospholipid Syndrome Repeat test NegativePositive Antiphospholipid Syndrome

22 Louisville APL Diagnostics Anticardiolipin ELISA publications n Harris EN. Annotation: antiphospholipid antibodies. Br J Haematology. 1990; 74:1-9 n Harris EN, Pierangeli SS. Anticardiolipin and lupus anticoagulant testing and significance. J Clin Immunol 1994; 17:1-8. n Harris EN, Pierangeli SS, Birch D. Anticardiolipin wet workshop report: Vth International Symposium on Antiphospholipid antibdies. AM J Clin Pathol 1994: 101: 616-624. n Harris EN, Pierangeli SS. “Equivocal” Antiphospholipid Syndrome. J Autoimm. 2000; 15:81-85. n Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol 2001:44:48-57. n Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11:269- 275. n Pierangeli SS, Harris EN. Anticardiolipin testing. Clin Chim Acta. 2005;

23 Louisville APL Diagnostics ELISAs for IgG and IgM aPL

24 Louisville APL Diagnostics ELISAs for IgG or IgM aPL

25 Louisville APL Diagnostics ELISAs for IgA aPL

26 Louisville APL Diagnostics Louisville APL Diagnostics, Inc web site: www.louisvilleapl.com email:support@louisvilleapl.com www.louisvilleapl.com

27 Louisville APL Diagnostics Silvia S. Pierangeli, Ph.D. Silvia S. Pierangeli, Ph.D.

Download ppt "UPDATE IN THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODIES SILVIA S. PIERANGELI, PhD LOUISVILLE APL DIAGNOSTICS, INC DORAVILLE, GA USA Louisville APL Diagnostics,"

Similar presentations

Chagas Tests: Development and Standardization

Chagas Tests: Development and Standardization
Nick Curry, MD, MPH Infectious Diseases Prevention Section

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advanced Diagnostics Laboratory AUTOANTIBODY OF THE MONTH Case history: A 24 year old woman is seen by her physician complaining of severe fatigue, joint.

Advanced Diagnostics Laboratory AUTOANTIBODY OF THE MONTH Case history: A 24 year old woman is seen by her physician complaining of severe fatigue, joint.
A Multi-Laboratory Evaluation of a Chromogenic Factor X Assay for Monitoring Oral Anticoagulation Therapy DL McGlasson 1*; PN Shaklee 2; 1 59 th Clinical.

A Multi-Laboratory Evaluation of a Chromogenic Factor X Assay for Monitoring Oral Anticoagulation Therapy DL McGlasson 1*; PN Shaklee 2; 1 59 th Clinical.
Unit 6 Diagnosis & Follow-up of HIV Infection

Unit 6 Diagnosis & Follow-up of HIV Infection
Anti-Phospholipid Antibody Syndrome The Annexin A5 Competition Assay as a Diagnostic Tool.

Anti-Phospholipid Antibody Syndrome The Annexin A5 Competition Assay as a Diagnostic Tool.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.

To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.
Laboratory Diagnosis of HSV Infection Peter Leone, MD Associate Professor of Medicine University of North Carolina.

Laboratory Diagnosis of HSV Infection Peter Leone, MD Associate Professor of Medicine University of North Carolina.
Enzyme Linked Immunosorbent Assay (ELISA)

Enzyme Linked Immunosorbent Assay (ELISA)
Blood Products Advisory Committee Meeting Harold S. Gaithersburg, MD December 14, 2010 Harold S. Margolis, MD Chief, Dengue Branch Centers for Disease.

Blood Products Advisory Committee Meeting Harold S. Gaithersburg, MD December 14, 2010 Harold S. Margolis, MD Chief, Dengue Branch Centers for Disease.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
1 Classification criteria for APS Clinical Criteria (Sydney 2004) Myakis et al. J Thromb Haemost 2006;4:295-306 Vascular thrombosis one or more clinical.

1 Classification criteria for APS Clinical Criteria (Sydney 2004) Myakis et al. J Thromb Haemost 2006;4: Vascular thrombosis one or more clinical.
Prof. Francesco Violi Università degli Studi di Roma “La Sapienza” APS.

Prof. Francesco Violi Università degli Studi di Roma “La Sapienza” APS.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Mechanisms of disease in the antiphospholipid syndrome A short tributededicated to the memory of Dr. Virgil Woods Jr.: brilliant and generous scientist,

Mechanisms of disease in the antiphospholipid syndrome A short tributededicated to the memory of Dr. Virgil Woods Jr.: brilliant and generous scientist,
Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.

Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.
Immunology vs. Serology Immunology –Study of immune system Serology –Detecting/measuring elements of humoral immune system (I.e., antibodies) –Help diagnose.

Immunology vs. Serology Immunology –Study of immune system Serology –Detecting/measuring elements of humoral immune system (I.e., antibodies) –Help diagnose.
Enzyme-linked Immunosorbent Assay

Enzyme-linked Immunosorbent Assay

Similar presentations

Ads by Google